Skip to content
    ARCH Venture Partners logo

    ARCH Venture Partners

    Chicago, Illinois, United StatesFounded 1986
    www.archventure.comLinkedIn
    Biotech & Life SciencesHealthcare

    ARCH Venture Partners is an early-stage venture capital firm that focuses on building and funding companies based on breakthrough science, primarily in life sciences, biotechnology, and related deep-tech domains. Their strategy involves partnering with leading scientists and research institutions to commercialize disruptive innovations.

    83% of their portfolio is in Biotech & Life Sciences. Deal activity increased 125% year-over-year (9 deals in the last 12 months). Average disclosed round size is $226.4M (across 82 rounds with reported amounts).

    Find people at ARCH Venture Partners on Goldilocks AI

    Portfolio

    84

    Fund Size

    $10.6B

    Top Stage

    Series A

    Last 12 Mo

    9

    Team

    SK

    Sean Kendall

    General Partner

    NT

    Nilay Thakar, Ph.D.

    Principal

    Steven Gillis

    Steven Gillis

    General Partner

    KC

    Keith Crandell

    Co-founder & Managing Director

    BC

    Brian Cuneo

    Senior Partner

    IC

    Inca Coman, Ph.D.

    Venture Partner

    JJ

    Joseph Jeong, Ph.D.

    Venture Partner

    LB

    Luciana Borio, M.D.

    Venture Partner

    AN

    Ari Nowacek, M.D, Ph.D.

    Partner

    MC

    Mary Chamberlain-Tharp, Ph.D.

    Managing Partner

    George Scangos, Ph.D.

    George Scangos, Ph.D.

    Associate

    CB

    Clinton Bybee

    Co-founder & Managing Director, Emeritus

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    84 investments
    CompanyRoundAmountDate
    VVizgenSeries C$48MJan 2026
    SciNeuro Pharmaceuticals logoSciNeuro PharmaceuticalsUnknown$53MDec 2025
    Paradigm Health logoParadigm HealthSeries B$78MDec 2025
    Aspen Neuroscience logoAspen NeuroscienceSeries C$115MNov 2025
    LLifordi ImmunotherapeuticsUnknown—Nov 2025
    Gate Bioscience logoGate BioscienceSeries B$65MNov 2025
    Elephas Biosciences Corporation logoElephas Biosciences CorporationSeries B$40MNov 2025
    Treeline Biosciences logoTreeline BiosciencesSeries A$200MSep 2025
    DDispatch BioUnknown$216MJul 2025
    Arbor Biotechnologies Inc logoArbor Biotechnologies IncSeries C$73.9MMar 2025
    Tenvie Therapeutics logoTenvie TherapeuticsSeries A$200MJan 2025
    Vilya, Inc. logoVilya, Inc.Series A$71MJun 2024
    XXaira TherapeuticsGrowth$1BApr 2024
    Xaira logoXairaSeed$1BApr 2024
    XXaira TherapeuticsGrowth$6.6BApr 2024
    XXaira TherapeuticsSeries A—Apr 2024
    Elephas Biosciences Corporation logoElephas Biosciences CorporationSeries C$55MJan 2024
    Human Immunology Biosciences (HI-Bio) logoHuman Immunology Biosciences (HI-Bio)Series B$95MJan 2024
    Remix Therapeutics logoRemix TherapeuticsSeries C$60MJan 2024
    Tome Biosciences logoTome BiosciencesSeries B$213MDec 2023
    Gate Bioscience logoGate BioscienceSeries A$60MNov 2023
    Magnet Biomedicine logoMagnet BiomedicineSeries A$50MSep 2023
    Generate:Biomedicines logoGenerate:BiomedicinesSeries C$273MSep 2023
    RRapport TherapeuticsSeries B$150MAug 2023
    LLightcast DiscoverySeries B$49MAug 2023
    Page 1 of 4

    Top Co-Investors

    GV (Google Ventures)18 shared
    Alexandria Venture Investments17 shared
    F-Prime Capital9 shared
    General Catalyst7 shared
    OrbiMed6 shared
    Illumina Ventures6 shared
    Foresite Capital6 shared
    Polaris Venture Partners6 shared
    Northpond Ventures6 shared
    Alaska Permanent Fund6 shared
    Section 325 shared
    Tao Capital Partners5 shared
    Casdin Capital5 shared
    Altitude Life Science Ventures5 shared
    Cormorant Asset Management4 shared
    Bezos Expeditions4 shared
    Atlas Venture4 shared
    Flagship Pioneering4 shared
    Mubadala Ventures4 shared
    NEA (New Enterprise Associates)4 shared

    Last updated: 15 April 2026